Concepedia

Publication | Open Access

Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study

DOIFull Paper Access

133

Citations

13

References

2016

Year

Rik Vandenberghe, Marie‐Emmanuelle Riviere, Angelika Caputo, Judit Sóvágó, R. P. Maguire, Martin R. Farlow, Giovanni Marotta, Raquel Sánchez‐Valle, Philip Scheltens, J. Michael Ryan,
Alzheimer s & Dementia Translational Research & Clinical Interventions

Abstract

Repeated CAD106 administration was generally well tolerated. CAD106 450 μg with alum adjuvant demonstrated the best balance between antibody response and tolerability.

References

YearCitations

Page 1